Jove
Visualize
Contáctanos

Videos de Conceptos Relacionados

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Anti-Tumor Immunity and Immunotherapy Efficacy.

Cancer research·2026
Same author

Context-dependent synthetic lethality - an emerging precision therapeutic approach.

Nature reviews. Cancer·2026
Same author

Discovery of INCB191358: A Potent and Selective DGKα/ζ Dual Inhibitor.

Journal of medicinal chemistry·2026
Same author

Discovery of a Selective and Potent Inhibitor of Cyclin-Dependent Kinase 12/13 Employing a Noncovalent Mechanism.

ACS medicinal chemistry letters·2026
Same author

Systematic cysteine scanning identifies a druggable pocket in oncogenic KRAS.

Cell chemical biology·2026
Same author

Enzyme replacement therapy for CLN1 batten disease that crosses the blood-brain-barrier.

Molecular genetics and metabolism·2026
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Video Experimental Relacionado

Updated: Jun 26, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Validación de objetivos de fármacos contra el cáncer.

John D Benson1, Ying-Nan P Chen, Susan A Cornell-Kennon

  • 1Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, USA.

Nature
|May 26, 2006
PubMed
Resumen
Este resumen es generado por máquina.

La validación de objetivos de fármacos contra el cáncer requiere la demostración de la eficacia clínica. Sin embargo, aún faltan criterios universalmente aceptados para la validación de objetivos en etapas tempranas, a pesar de su utilidad para guiar la investigación.

Más Videos Relacionados

Assessing Specificity of Anticancer Drugs In Vitro
09:39

Assessing Specificity of Anticancer Drugs In Vitro

Published on: March 23, 2016

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Videos de Experimentos Relacionados

Last Updated: Jun 26, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Assessing Specificity of Anticancer Drugs In Vitro
09:39

Assessing Specificity of Anticancer Drugs In Vitro

Published on: March 23, 2016

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Área de la Ciencia:

  • Oncología Oncología.
  • Farmacología Farmacología.
  • Investigación biomédica en la investigación biomédica.

Sus antecedentes:

  • La verdadera validación de un objetivo de fármaco contra el cáncer se basa en la eficacia clínica de un agente terapéutico que actúa a través de ese objetivo.
  • La validación de objetivos en etapas tempranas es deseable para guiar las inversiones en el descubrimiento de fármacos.
  • Los estudios de validación actuales informan la investigación del cáncer, pero carecen de criterios universales.

Objetivo del estudio:

  • Discutir el concepto y la conveniencia de la validación de la diana del fármaco contra el cáncer en etapa temprana.
  • Para resaltar la brecha en los criterios establecidos y universales para la validación de objetivos.
  • Para subrayar la importancia de los resultados de validación en la investigación del cáncer.

Principales métodos:

  • Revisión de la literatura y análisis conceptual de los principios de validación de objetivos de drogas.
  • Discusión de la relación entre la validación de objetivos y el desarrollo clínico de fármacos.
  • Análisis del estado actual de los criterios de validación en la investigación del cáncer.

Principales resultados:

  • La eficacia clínica y la acción en el objetivo son las métricas de validación final para los objetivos de medicamentos contra el cáncer.
  • La validación temprana es un objetivo práctico, pero carece de criterios estandarizados y universales.
  • Los estudios de validación existentes ofrecen orientación, pero no están definidos universalmente.

Conclusiones:

  • La definición de criterios universales para la validación de objetivos de fármacos contra el cáncer en etapas tempranas sigue siendo una necesidad no satisfecha.
  • Si bien la validación clínica es definitiva, los primeros indicadores son cruciales para el descubrimiento eficiente de fármacos.
  • El desarrollo adicional de metodologías de validación estandarizadas es esencial para el avance de las terapias contra el cáncer.